公开(公告)号：US20180125892A1

公开(公告)日：2018-05-10

申请号：US15727402

申请日：2017-10-06

Applicant: Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes

IPC: A61K35/17 ,  A61K38/17 ,  C07K16/28 ,  C12N15/85 ,  A61P35/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US20160311917A1

公开(公告)日：2016-10-27

申请号：US15105082

申请日：2014-12-19

Applicant: Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC: C07K16/30 ,  C07K14/705 ,  C07K14/715 ,  C12N5/0783 ,  A61K39/395 ,  A61K48/00 ,  A61K38/17 ,  C12N15/85 ,  A61K31/436 ,  C07K14/725

CPC classification number: C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/0011 ,  A61K39/39558 ,  A61K48/0058 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  C12N2740/15041

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Abstract translation: 提供了用于治疗与间皮素表达相关的疾病的组合物和方法。 还提供了对间皮素特异性的嵌合抗原受体（CAR），编码它的载体和包含间皮素CAR的重组T细胞。 还提供了施用表达包含间皮素结合结构域的CAR的遗传修饰的T细胞的方法。

公开(公告)号：US20160311907A1

公开(公告)日：2016-10-27

申请号：US15105074

申请日：2014-12-19

Applicant: Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

Inventor： Jennifer Brogdon ,  Boris Engels ,  David Jonathan Glass ,  Brian Granda ,  John Hastewell ,  Andreas Loew ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  William Raj Sellers ,  Huijuan Song ,  Brian Edward Vash ,  Jan Weiler ,  Qilong Wu ,  Li Zhou

IPC: C07K16/28 ,  A61K35/17 ,  C12N9/90 ,  C07K14/705 ,  C07K14/71 ,  C07K14/725 ,  A61K31/436

CPC classification number: C07K16/2863 ,  A61K31/436 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K14/71 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/41 ,  C07K2319/43 ,  C07K2319/70 ,  C12N9/1205 ,  C12N9/90 ,  C12Y502/00

Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Abstract translation: 提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。 例如，RCAR可以包含二聚转换开关，其在二聚化分子的存在下可以将细胞内信号结构域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域 。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

公开(公告)号：US20190000944A1

公开(公告)日：2019-01-03

申请号：US16065387

申请日：2016-12-21

Applicant: Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe ,  Novartis AG ,  The Trustees of the University of Pennsylvania ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20170260268A1

公开(公告)日：2017-09-14

申请号：US15511973

申请日：2015-09-17

Applicant: Gregory BEATTY ,  Boris ENGELS ,  Neeraja IDAMAKANTI ,  Carl H JUNE ,  Andreas LOEW ,  Michael C. MILONE ,  Huijuan SONG ,  Enxiu WANG ,  Qilong WU

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  A61K35/17 ,  C07K14/74 ,  C07K14/705

CPC classification number: C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20170081411A1

公开(公告)日：2017-03-23

申请号：US15126037

申请日：2015-03-13

Applicant: Boris Engels ,  Andreas Loew ,  Michael C. Milone ,  Li Zhou ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Boris Engels ,  Andreas Loew ,  Michael C. Milone ,  Li Zhou

IPC: C07K16/28 ,  C12N15/62 ,  A61K38/17 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725

CPC classification number: C07K16/2863 ,  A61K38/00 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/3955 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/55561 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70575 ,  C07K16/00 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/22 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/10 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  C07K2319/73 ,  C12N15/62

Abstract: Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.